Irinotecan and Docetaxel for Oesophageal Cancer
Author Information
Author(s): Lordick F, von Schilling C, Bernhard H, Hennig M, Bredenkamp R, Peschel C
Primary Institution: Technical University of Munich
Hypothesis
The study aims to assess the activity and toxicity of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer.
Conclusion
The combination of irinotecan and docetaxel showed moderate activity and manageable toxicity in patients with pretreated oesophageal cancer.
Supporting Evidence
- 12.5% of patients achieved a partial remission.
- 33.3% of patients had disease stabilization.
- The median survival time was 26 weeks.
- Patients with disease stabilization had a median survival of 51 weeks.
Takeaway
Doctors tested a new medicine combination for patients with a tough type of cancer, and while it didn't work for everyone, some patients felt better for a while.
Methodology
Patients with advanced oesophageal cancer were treated with irinotecan and docetaxel, and their responses were evaluated after several cycles of treatment.
Limitations
The small sample size and the high toxicity observed limit the generalizability of the results.
Participant Demographics
Median age was 58.5 years, with 18 males and 6 females; all had previously received cisplatin-based treatment.
Statistical Information
P-Value
P=0.183
Confidence Interval
95% CI=2.7–32.4%
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website